Brendan McCann (Glasgow, Scotland, UK)
Scottish Clinical Management Guidelines for MCC

Candice Church (Seattle, WA, USA)
The Merkel polyomavirus “TCR-ome” as a tool to monitor anti-tumor immunity: let’s collaborate!

Sara Passerini (Rome, Italy)
Merkel Cell Polyomavirus (MCPyV) and the DNA Damage Response (DDR): Expression Analysis of DDR Genes in MCPyV-positive Merkel Cell Carcinoma and in Human Dermal Fibroblasts

Xiaohao Wang (Stockholm, Sweden)
Merkel cell polyomavirus oncoprotein promotes BAG3-mediated aggresome formation

Büke Celikdemir (Würzburg, Germany)
RB1 knockdown and expression of BCL-2, EZHIP, constitutively active AKT, and L_MYC in SCC cell lines result in loss of H3K27me3, disruption of cell adhesion, and enhanced anchorage-independent cell survival

Peter Ch’en (Seattle, WA, USA)
Real-world outcomes of patients receiving salvage therapies for immune checkpoint inhibitor-resistant MCC: a rationale for future clinical trials

Libuše Janská (Stockholm, Sweden)
Decoding Immune-Tumor Interactions: Cell-Surface Mapping in MCC Under Immune Checkpoint Inhibition

Dan Hippe (Seattle, WA, USA)
When Should We Stop? Predicting Progression Risk After Immunotherapy Discontinuation in MCC